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Imagine a day when electrical impulses are a mainstay of medical treatment. Your clinician
will administer electroceuticals that target individual nerve fibres or specific brain circuits to
treat an array of conditions. These will modulate the neural impulses that control the body,
repair lost function and reinstate a healthy balance. They could coax insulin from islet cells,
regulate food intake, and control inflammation. They may treat pressing major ailments such
as hypertension, diabetes, obesity, heart failure, pulmonary and vascular disease.
All this is within reach, we argue, if researchers from disparate disciplines in academia and
industry work together. We herewith outline what needs to be done to bring about
electroceuticals, and unveil a public-private research initiative and award that aim to
catalyse the field.
Speak the language
Electrical impulses — action potentials — are the language of our nervous system,
transmitted around the body. Virtually all organs and functions are regulated through circuits
made of neurons communicating through such impulses1. Two features make these circuits
excellent targets for therapeutic intervention. First, they comprise discrete components –
interconnected cells, fibre tracts and nerve bundles – allowing for pinpoint intervention.
Second, their control is conveyed by the patterns of action potentials, which can be altered
for treatment.
Already, devices harness electrical impulses to treat disease. Pacemakers and defibrillators
save millions of lives each year; deep brain stimulators dramatically improve the quality of
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life for people with Parkinson's disease and depression; sacral nerve stimulation restores
some bladder control in paraplegics, and vagus nerve stimulation shows clinical benefits in
diseases ranging from epilepsy to rheumatoid arthritis2. But these devices do not target
specific cells within circuits, limiting their scope for expansion.
Neural tissue is compact, and a range of different, often unrelated circuits run close together
through brain regions and in peripheral nerves. Currently, devices activate or inhibit many
cells across an area of tissue indiscriminately, muddying clinical effects. For example,
electrodes that stimulate the vagus nerve enclose approximately 100,000 fibres that
innervate many different internal organs. Similarly, deep brain stimulation for Parkinson's
disease affects many more cells than those controlling movement, leading to emotional and
cognitive side effects. In natural urinary control, opposite signals in small adjacent nerve
fibres simultaneously contract the bladder and relax the urethral sphincter, an elegant
process poorly mimicked by today's devices.
Neither do neurostimulation devices yet generate natural patterns of action potentials.
Signalling is typically blocked or stimulated in stereotyped ways, rather than modulated on
the millisecond scale. Research on the neural circuit for hunger elegantly shows the
importance of such precise modulation of action potentials. Full stimulation or ablation of
cells in the hypothalamic arcuate nucleus shifts mice from voracious eating to anorexia.
However, the level of food intake can be finely modulated by the number and frequency of
action potentials triggered in specific cells3. Similarly, single action potentials in small sets
of cortical neurons in mice have been shown to encode sensory input or perceptions4. In
other words, a precise set of action potentials applied to small numbers of cells can define
the biological control a neural circuit exerts.
Path to precision
We believe that it is now possible to transcend these constraints and create medicines that
control action potentials in individual and functional groups of neurons in adaptive ways
fully compatible with biological function.
Many of the stepping stones are already in place, thanks to recent advances in a variety of
disciplines. For example, disease-specific neural circuits are starting to be anatomically and
functionally traced, as evidenced by the neural reflex that controls levels of inflammatory
mediators5. Tools with cellular-level resolution, such as optogenetics, have improved our
ability to analyse the signals in circuits and provide a mechanism by which future
electroceuticals could elicit action potentials6. Architectures for electrodes able to interface
with individual neurons are starting to emerge through efforts to control prosthetic limbs and
generate brain-machine interfaces. Neuromorphic chips allowing low-power and local
computation are being designed7. Neural signal processing has advanced driven by cochlear
and retinal implants. Nanotechnology has delivered energy harvesting approaches to power
microdevices8. And finally, percutaneous neurosurgery is making precision intervention
possible, centrally and peripherally, as evidenced by precision procedures to remove
herniated disc material or creating drainage within cerebral ventricles.
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The first logical step towards electroceuticals is to better map neural circuits associated with
disease and its treatment. This mapping needs to happen at two levels. On an anatomical
level, we need to map disease-associated nerves and brain areas and identify the best points
for intervention. On the signalling level, we need to decode the neural language at these
intervention points so that we can develop a dictionary of patterns associated with health and
disease states, a project synergistic with international drives to map the human brain now
being launched9. In circuits altered by disease we will also need to establish the disease
effects of introduced electrical impulses and the patterns that yield the most effective
therapeutic responses. Developing the technology to record from and stimulate larger set of
central and peripheral neurons will be critical to this pursuit of mapping disease-associated
circuits.
This type of research corresponds to the target identification and validation steps that lie at
the core of modern molecular drug discovery. The emerging circuit maps will provide the
specifications for the design of future treatment devices. Early prototypes might use
microchip-controlled electrode arrays, as are used today in interfaces for prosthetic limbs
(Figure 1), whereas second generation micro- and nanoscale devices may leverage light,
mechanical, magnetic, or the body's own chemical energy to control electrical impulses in
specific cells within targeted circuits.
Multidisciplinary journey
How will all this come about? Disease biologists will need to work with neuroscientists on
circuit mapping and bioinformaticians on identifying the action potential signatures of
disease. Generating the treatment device (Figure 1) will call upon bioengineers to design
biocompatible interfaces in collaboration with electrical engineers developing circuits for
real time processing, nanotechnologists creating energy sources, and neurosurgeons ensuring
these designs can be implanted and connected. Researchers need to embrace languages and
tools from other fields and maybe even dream differently: much of the challenge lies in
translating biological understanding into engineering specifications.
We think initial progress will come from targeting circuits with accessible peripheral
intervention points. For example, it has been shown that hypertension can be controlled
through signals in the carotid sinus and renal nerves, and cytokine production in rheumatoid
arthritis through the splenic nerve. A range of other conditions across cardiovascular,
metabolic and respiratory, inflammatory and autoimmune areas should have similarly
accessible intervention points, given these organs and functions are under neural control.
The electroceuticals we envision should be adaptive or “closed loop”, meaning they record
incoming action potentials as well as physiological parameters, analyse this data in real time,
and modulate the signals in the neural circuit based on the analysis. This together with the
spatial targeting of a specific set of neurons underpin the exquisite specificity and high
therapeutic index we expect from electroceuticals. However, this can only be realised if the
different required disciplines come together early on.
Finally, we expect that the resulting interdisciplinary advances can also be brought to bear
on the emerging activity maps of brain circuits. Correcting central nervous system disorders
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with treatment in their own language, and at a spatio-temporal resolution commensurate
with our most complex of organs, could possibly, in the long run, be the most revolutionary
aspect of electroceuticals.
Pitfalls
Critics will argue that we underestimate the complexity of the nervous system, the
challenges in reliably, durably, and non-disruptively addressing a larger number of
individual neurons, and the sheer volume of neural information flowing through these
circuits. We counter that miniaturisation and handling “big data” are arguably two of the
most rapid areas of scientific progress in the past decade. Further, starting with peripheral
intervention points and simpler circuits should help.
There are also a few noteworthy unknowns, which we will resolve only by putting the
approach to test. One is to what extent mapping of the neural language translates from
animal models to the human setting; a second is in which diseases the relevant neural
circuits will be sufficiently dominant to reverse or control disease progression; and a third is
the level of circuit redundancy or other plasticity, that could limit the efficacy of treatment.
Catalyzing the field
In academia and at GlaxoSmithKline (GSK) we are mobilizing resources for this journey.
The University of Pennsylvania's new Center for Neuroengineering and Therapeutics
opening this summer will span multiple schools across campus, including Medicine,
Engineering and Business. Penn investigators are already mapping neural circuits in vivo,
building and deploying novel nano and microscale devices to modulate circuits at the
neuronal level, mining “big” neural data using cloud computing, and translating these
technologies into human use, such as in new antiseizure devices.
At the Feinstein Institute for Medical Research, we are trying to establish the neural code
that underlies diseases of immunity and inflammation, to identify intervention points, and to
conduct exploratory clinical work. Our results indicate it is feasible to identify and
manipulate neural signals specific to different inflammatory mediators in standard
laboratory models. At the Massachusetts Institute of Technology, we are creating and
distributing the genetic codes, parts lists, software, and other technologies needed to map
and modeulate neural circuits, ranging from optogenetics5 to scalable and automated
electrophysiology10.
Confident that this field will deliver real medicines, GSK is committed to acting as a catalyst
through three immediate steps: first is the launch of a funding program in April 2013 to
stimulate exploratory work mapping disease-associated neural circuits by up to 40 fully
funded researchers in up to 20 labs external to the company. Initial one-year funding will be
awarded after a rapid review and approval process (~1 month). Prepublication results will be
shared with other researchers in the growing network and any intellectual property created
will remain with the inventors. Throughout this exploratory phase, the network will be
encouraged and supported to shape longer-term research and development efforts. Second,
the company will organise a global forum in December 2013 for a broader set of research
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leaders to chart an integrated path. Third, GSK will offer a $1 million innovation prize to
overcome a key hurdle in the field that will be identified collectively by this community and
launched after the global forum.
Clearly, open innovation and flexible ways of pooling intellectual property will be
important. As the poet Cesare Pavese put it: “To travel far and fast, travel light: Take off all
your envies, jealousies, unforgiveness, selfishness and fears.” Together we can bring about a
new era of electroceuticals.
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Figure 1.
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